Clinical trial · Interventional
Somatostatin Receptor Imaging in NPC, EBV Related Cancers
Somatostatin Receptor Imaging in Nasopharyngeal Cancer, Epstein-Barr Virus (EBV) Related Cancers and Other Rare Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study aims to describe the avidity of somatostatin receptors in locally advanced, metastatic and locally recurrent nasopharyngeal cancer (NPC) and to determine the proportion of NPC patients with high somatostatin receptor density that may benefit from future somatostatin targeted therapeutic trial plans. The investigators also aim to determine the presence of somatostatin receptors in other EBV related cancers.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Epstein-Barr Virus Related Carcinoma | EBV-Related Carcinoma | ALIAS | 0.90 |
| Nasopharyngeal Cancer | Malignant Nasopharyngeal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| FDG-PET | Radiation | — | UNRESOLVED |
| Galium-68 DOTATATE | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- PET imaging
- interventionNames
- Radiation: FDG-PET
- Radiation: Galium-68 DOTATATE
Primary outcomes (1)
- measure
- Amount of tracer uptake in the tumour lesions of NPC patients
- timeFrame
- From time of tracer injection to time the scan is performed
- description
- The maximum standardized uptake values (SUVmax) will be measured. If the average SUVmax of all the lesions is more than 10, the patient will be considered to have an overall high somatostatin receptor density.
Secondary outcomes (3)
- measure
- Amount of tracer uptake in the tumour lesions of patients with EBV related cancers
- timeFrame
- From time of tracer injection to time the scan is performed
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * Locally advanced, metastatic or locally recurrent NPC that are going for FDG PET as part of their investigations * Patients that have gone for Ga-68 DOTATATE imaging before are eligible for repeat imaging * Histologically confirmed NPC * Above 21 years of age Exclusion Criteria: * Patients below 21 years of age * Pregnant and breast feeding ladies
References
Publications (0)
Data not yet available